News

The South Korean Ministry of Food and Drug Safety (MFDS) has recently cleared Pluristem’s upgraded manufacturing process in its new facility in Haifa, Israel. The cells produced at

At present, Entyvio is approved for inducing and maintaining clinical response and remission, improving endoscopic appearance of the mucosa. The drug secured the approval to achieve corticosteroid-free remission

The ORCHARRD trial failed to meet its primary endpoint as there was no statistically significant difference in progression free survival (PFS) between the treatment arms. GSK said that

It is the first patent granted for Zestra in Canada and is valid until June 2021, while it is the tenth patent that the company’s wholly-owned subsidiary, Semprae

As part of the deal, Ophthotech will receive an immediate payment of an upfront fee of $200m plus potential future recruitment and other milestone payments. Additionally, Ophthotech is

The partnership will build advanced value in Takeda’s operations by consolidating IT platforms across the organization. Under the deal, Wipro will build and maintain a global platform for

Primary liver cancer (hepatocellular carcinoma) is a particularly aggressive cancer resistant to chemotherapy treatments. Hepatocellular carcinoma represents the second leading cause of cancer-related deaths worldwide and it has

Elotuzumab is being co-developed with AbbVie, while BMS is leading the commercialization of the agent. The drug was granted this designation for use in combination with lenalidomide and

Nintedanib is the first targeted treatment for IPF to consistently meet the primary endpoint in two international Phase III trials with identical design. In the two 52 week